Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial

P.R. Feldman*, K.M. Fiebig*, C. Piwko, B.M. Mints, D. Brown, D.J. Cahan, J. Guevara-Aguirre

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number100978
Number of pages10
JournalEClinicalMedicine
Volume37
DOIs
Publication statusPublished - 1 Jul 2021

Keywords

  • Androgenetic alopecia
  • Telogen effluvium
  • Female pattern hair loss
  • Hair restoration
  • Minoxidil
  • Finasteride
  • Botanical
  • Women's health
  • Menopause
  • Senescence
  • Aging
  • Wnt/beta-catenin
  • Multi-targeting
  • Stem cell
  • Hair regeneration
  • Regenerative medicine
  • COVID-19
  • PRP
  • TOPICAL MINOXIDIL
  • HAIR LOSS
  • MECHANISMS
  • MEN

Cite this